Missing a GOLDen opportunity in gastric cancer
Mené sur 643 patients asiatiques atteints d'un cancer de l'estomac de stade avancé, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout de l'olaparib au paclitaxel en traitement de seconde ligne
Advanced gastric cancer has a poor prognosis; currently available palliative treatments result in survival of less than 18 months for most patients. Although immune checkpoint blockade has shown promise in chemorefractory gastric cancer, the modest benefit associated with anti-PD-1 therapy means that alternative gastric cancer vulnerabilities should continue to be explored.1 Defective homologous recombination, classically found in BRCA-mutated tumours, has been successfully exploited by poly-ADP-ribose polymerase (PARP) inhibitors in ovarian, breast, and prostate cancer
The Lancet Oncology , commentaire, 2016